Condition
Stage IIA1 Cervical Cancer FIGO 2018
Total Trials
4
Recruiting
0
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
P 2 (1)
Trial Status
Active Not Recruiting3
Withdrawn1
Clinical Trials (4)
Showing 4 of 4 trials
NCT04580771Phase 2Active Not Recruiting
A Vaccine (PDS0101) and Chemoradiation for the Treatment of Stage IB3-IVA Cervical Cancer, the IMMUNOCERV Trial
NCT04622670Not ApplicableActive Not Recruiting
Yoga Therapy During Chemotherapy and Radiation Treatment for the Improvement of Physical and Emotional Well-Being in Patients With Stage IB2-IIIB Cervical Cancer
NCT04574635Active Not Recruiting
Human Papilloma Virus (HPV) Circulating Tumor DNA (ctDNA) in Cervical Cancer
NCT05093712Withdrawn
Patient-Informed Educational Intervention for the Improvement of Cervical Cancer Literacy
Showing all 4 trials